Trenbolone is an anabolic steroid. It is used on livestock to increase muscle growth and appetite. Trenbolone compounds have a binding affinity for the androgen receptor three times as high as that of testosterone. Once metabolized, the drugs have the effect of increasing nitrogen uptake by muscles, leading to an increase in the rate of protein synthesis. It also has the secondary effects of stimulating appetite, reducing the amount of fat being deposited in the body, and decreasing the rate of catabolism. Short-term side effects include insomnia, high blood pressure, increased aggression, night sweats, and libido.

Tocophersolan (Vedrop, tocofersolan) or d-alpha-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) is a watersoluble derivative of the natural active (d-alpha) isomer of vitamin E. The active constituent of the medicinal product is essentially vitamin E (alpha tocopherol). Chronic congenital or hereditary cholestasis is a clinical condition where vitamin E deficiency results from an impaired bile secretion. Decreased intestinal absorption observed in chronic congenital or hereditary cholestatic patients is due to decreased bile secretion and the resulting decrease in intestinal cellular absorption. As a result, fatsoluble vitamins (i.e. vit. E) are not absorbed properly and deficiency can occur. Tocophersolan (Vedrop) is used to treat or prevent vitamin E deficiency (low vitamin E levels). It is used in children up to the age of 18 years who have congenital or hereditary chronic cholestasis and who cannot absorb vitamin E from the gut. Tocophersolan (Tocofersolan) can be absorbed from the gut in children who have difficulty absorbing fats and vitamin E from the diet. This can increase vitamin E levels in the blood and help to prevent neurological deterioration (problems in the nervous system) due to vitamin E deficiency. No treatment-related findings were reported, as all clinical observations and findings at autopsy were similar in treatment and control groups. In many of the studies, the LD50 was not determined as tocofersolan was well tolerated.

Isoflupredone is a veterinary drug used in cows, pigs and horses for the treatment of wide range of conditions: ketosis, musculoskeletal disorders, hypersensitivity, infections, inflammatory diseases, etc. The drug belongs to the class of corticosteroids and exerts its therapeutic effect by binding to glucocorticoid and mineralocorticoid receptors of animals.

Barium hydroxide, Ba(OH)2, is also known as baryta. Barium hydroxide crystallizes as the octahydrate, which can be converted to the monohydrate by heating in air. The anhydrous hydroxide has only a secondary industrial importance; the monohydrate and octahydrate are used in industry on a far larger scale. Barium hydroxide, especially the monohydrate, is used to produce organic barium compounds such as additives for oil and stabilizers for plastics. In addition, barium hydroxide is used for dehydration and deacidification, especially for removing sulfuric acid from fats, oils, waxes, and glycerol.

Barium hydroxide, Ba(OH)2, is also known as baryta. Barium hydroxide crystallizes as the octahydrate, which can be converted to the monohydrate by heating in air. The anhydrous hydroxide has only a secondary industrial importance; the monohydrate and octahydrate are used in industry on a far larger scale. Barium hydroxide, especially the monohydrate, is used to produce organic barium compounds such as additives for oil and stabilizers for plastics. In addition, barium hydroxide is used for dehydration and deacidification, especially for removing sulfuric acid from fats, oils, waxes, and glycerol.

Atosiban (brand name Tractocile) is a competitive antagonist of human oxytocin at receptor level. In rats and guinea pigs, atosiban was shown to bind to oxytocin receptors, to decrease the frequency of contractions and the tone of the uterine musculature, resulting in a suppression of uterine contractions. Atosiban was also shown to bind to the vasopressin receptor, thus inhibiting the effect of vasopressin. Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with: − regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes − a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50% − a gestational age from 24 until 33 completed weeks − a normal foetal heart rate. Atosiban does not have U.S. Food and Drug Administration (FDA) approval for use in the United States.